AstraZeneca: Hepatolenticular Degeneration trials

The registry lists 11 Hepatolenticular Degeneration studies with AstraZeneca as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 4Phase 2 3Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy ParticipantsCompletedNCT05641311Phase 1Results posted
• Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseTerminatedNCT05047523Phase 3Results posted
• Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840CompletedNCT04573309Phase 2Results posted
• A Study of the Cardiac Effects of ALXN1840 in Healthy AdultsCompletedNCT04560816Phase 1Results posted
• Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy ParticipantsCompletedNCT04526210Phase 1Results posted
• Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.CompletedNCT04526197Phase 1Results posted
• Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840CompletedNCT04422431Phase 2Results posted
• Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseaseTerminatedNCT03403205Phase 3Results posted
• The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care TreatmentCompletedNCT02763215Results posted
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease PatientsCompletedNCT02273596Phase 2Results posted
• Early Access Program for ALXN1840 in Patients With Wilson DiseaseNo longer availableNCT05686564